)
Visual24 Oct 2025
The rise of Alphabet
Verici Dx (VRCI) investor relations material
Verici Dx H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary7 Oct, 2025
Executive summary
Achieved Medicare coverage for Tutivia in April, enabling full commercial launch, revenue recognition, and rapid payment cycles.
Raised over £6.35m in July, extending cash runway into at least H2 2026 and supporting commercial scale-up.
Transitioned to commercial stage with two validated products: Tutivia and PTRA (Clarava), with licensing agreement in place for PTRA with Thermo Fisher.
Expanded commercial team, now up to four salespeople and additional clinical support, driving growth and onboarding 30 transplant centers (16% of US volume).
Maintained revenue targets for the year, with strong momentum and significant acceleration in testing volumes expected in Q4, Q1, and H2 2025.
Financial highlights
Revenue for the period was $1.9m: $1.16m from Tutivia testing and $0.75m from Thermo Fisher licensing.
EBITDA loss for the period was $2.8m.
Cash at end of June was $0.5m, increasing to $5.3m at end of September after fundraising.
Net cash outflow from operating activities was $3.5m.
Loss per share was $0.01 for H1 2025.
Outlook and guidance
Revenue target for 2025 remains at $3.2m for Tutivia, with significant volume acceleration expected in H2 2025 and beyond.
Growth expected from new center onboarding and expanded sales team, with Q4 and Q1 highlighted as key periods.
Focus remains on U.S. market; global expansion considered longer-term.
Funds in place to support growth and market expectations for full-year performance.
How will Tutivia penetrate non-Medicare market?
Quantify expected PTRA royalty/milestone revenue.
What is the commercialization plan for Protega?
Impact of commercial payer rates on avg. price
When will new centers significantly impact revenue?
Quantify CMS initiative's impact on testing demand
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Verici Dx earnings date
H2 202530 Jun, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Verici Dx Plc is an immuno-diagnostics development company that specializes in the kidney transplantation market. The company's focus is on creating prognostic and diagnostic tests for kidney transplant patients, aiming to improve patient outcomes through personalized medical management. Verici Dx commercializes RNA signature-based tests that leverage artificial intelligence and transcriptomic analysis to provide insights into the immune response and other biological pathway signals crucial for the prognosis of risk of injury, rejection, and graft failure in transplant patients. These tests form a comprehensive kidney transplant platform designed for personalized patient and organ response risk assessment. Verici Dx's lead products include Tutivia, a post-transplant test aimed at detecting acute rejection, including sub-clinical rejection, and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is headquartered in Penarth, Wales and its shares are listed on the London Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage